Triple Nano-platform Blocking CD44 Prevents Pancreatic Cancer Liver Metastasis Triggered by Dyslipidemic Fatty Liver
Background
Pancreatic cancer is an incurable cancer with a 5-year survival rate of around 10% due to rare early symptoms and invasion into adjacent organs or blood vessels at the time of diagnosis. In particular, the frequency of early liver metastasis is high, and the median survival period for patients with distant metastasis is less than one year.
Metabolic dysfunction-associated fatty liver disease (MAFLD), which has recently surged, has emerged as a risk factor promoting pancreatic cancer progression and liver metastasis. This is because the liver microenvironment, altered by lipid accumulation and inflammation, becomes a breeding ground that facilitates the colonization of circulating cancer cells.
However, the specific molecular targets linking fatty liver lesions and pancreatic cancer infiltration have not been identified to date. Existing standard chemotherapies based on Gemcitabine have remained at low response rates because they cannot overcome the dense fibrosis barrier and immunosuppressive microenvironment. This is because there have been repeated concerns that the conventional approach, centered on single therapeutic agents, makes it difficult to prevent the fatal spread of liver metastasis.
Key Findings
Researchers at Qingdao University in China analyzed public clinical databases and patient tissue specimens, and conducted single-cell RNA sequencing (scRNA-seq) on animal models. The analysis revealed that Cluster of Differentiation 44 (CD44), a cell surface glycoprotein receptor, is a key driver promoting pancreatic cancer malignancy and liver metastasis in the MAFLD environment.
In patient cohort data, the high CD44 expression group had a significantly lower overall survival rate compared to the low expression group. In liver metastatic lesions of animal models with MAFLD, CD44 expression levels were markedly elevated. This suggests that CD44 is involved in the process by which lipid accumulation in liver tissue enhances the metastatic potential and stemness of cancer cells.
To overcome therapeutic limitations, the researchers designed a nanocarrier that integrates chemotherapy, photothermal therapy, and gene immunotherapy. The GIR@Lip particle simultaneously delivers these three agents within a liposomal platform synthesized from the cationic lipid DOTAP and cholesterol.
The GIR@Lip nanoparticles were produced to incorporate the standard anticancer drug Gemcitabine, the near-infrared absorbing photothermal sensitizer IR780, and small interfering RNA (siRNA) that inhibits CD44 expression. The particles exhibit uniform size distribution, excellent stability, and high photothermal conversion efficiency.
In experiments using the KPC cell line (derived from pancreatic cancer in mice with Kras and p53 mutations), GIR@Lip inhibited cancer cell proliferation and blocked invasive potential. Under near-infrared irradiation, it induced CD44 expression suppression and cancer cell death.
Antitumor efficacy was also confirmed in in vivo animal evaluations. Intravenously administered GIR@Lip exhibited a tendency to accumulate specifically in liver metastatic lesions. In the laser-treated group of mice, the number of liver metastatic nodules significantly decreased compared to the control group.
Tumor-associated macrophages (TAMs), which had supported tumor growth, were massively repolarized into M1-type macrophages that attack cancer cells. The activation of the anticancer immune response was prominent, with increased infiltration of CD4+ and CD8+ T cells within the tumor.
Significance and Outlook
This study elucidated the central role of CD44 in the pathway by which metabolic dysfunction-associated steatotic liver disease (MASLD) accelerates distant metastasis of pancreatic cancer, and proposed a therapeutic model to block this using a complex nanocarrier. It is regarded as an achievement that demonstrates the synergistic potential of triple therapy combining gene silencing, thermal ablation, and systemic immune activation, thereby overcoming the limitations of single-agent anticancer drug administration.
Technical challenges remain to be addressed for clinical implementation. The key lies in the parallel advancement of optical medical device technology capable of safely and uniformly delivering near-infrared laser light to liver metastatic lesions deep within the patient's abdomen.
Establishing a Good Manufacturing Practice (GMP) mass production process for multi-component complex liposomes is also considered an essential step. Preclinical safety verification to rule out the risk of long-term toxicity in the body or accumulation in non-target organs is equally critical. Overcoming these technical barriers positions this approach as a promising practical therapeutic alternative for patients with incurable metastatic cancer co-occurring with metabolic diseases.
Metabolic dysfunction-associated fatty liver disease (MAFLD) has emerged as a novel risk factor for pancreatic cancer, particularly early liver metastasis. However, the underlying mechanisms and effective therapeutic strategies remain largely unclear. Here, based on clinical databases, patient tissue samples, and single-cell sequencing of mouse models, we identified CD44 as a key contributor to MAFLD-associated pancreatic cancer progression. High CD44 expression was significantly associated with poor survival in patients with pancreatic cancer and was further elevated in MAFLD-associated liver metastatic lesions. Given the limited efficacy of single treatments, we developed a cationic DOTAP/cholesterol liposomal nanoplatform co-loaded with gemcitabine, IR780, and CD44 siRNA (GIR@Lip) for combined chemotherapy, photothermal therapy, and immunotherapy. GIR@Lip nanoparticles exhibited excellent size uniformity, stability, and photothermal conversion efficiency, which could efficiently inhibit KPC cells' viability, migration and invasion, downregulate CD44 expression and stimulate immune response. Furthermore, GIR@Lip efficiently accumulated in tumor tissues in vivo, exhibiting a significant reduction in liver metastatic lesions and remodeling M1-type tumor-associated macrophages (TAMs) into CD4
This study provides insights into the identification of high-risk groups for pancreatic cancer among patients with rapidly increasing metabolic dysfunction-associated steatotic liver disease (MASLD) and offers a basis for precision targeted therapy to inhibit fatal early hepatic metastasis. In actual clinical practice, a customized treatment protocol can be devised for patients diagnosed with liver metastases by administering an intravenous injection of a targeted nano-therapeutic containing CD44-inhibiting RNA and a photothermal sensitizer, instead of existing single-agent anticancer chemotherapy, followed by local near-infrared laser irradiation guided by laparoscopic endoscopy. This provides direct evidence for the development of next-generation therapeutics that simultaneously achieve local control of metastatic cancer and systemic anticancer immune induction by converting the microenvironment of immune-cold tumors, which were unresponsive to existing anticancer drugs, into an immune-active state.